Emma Link

ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

Nathan Lawrentschuk, Roslyn Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Shakher Ramdave, LihMing Wong, Kim Taubman, SzeTing Lee, Edward Hsiao, Michelle Nottage, Ian Kirkwood, Emma Link, Alan Herschtal, Petra Marusic, Anetta Matera, Amir Iravani, et al.

Conference Proceedings  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Madeleine T King, Emma K Link, Tim J Whelan, Ivo A Olivotto, Ian Kunkler, Antonia Helen Westenberg, Guenther Gruber, Penny Schofield, Boon H Chua

Journal article  |  2020  |  The Lancet Oncology

BACKGROUND: BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boos..

Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

Michael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Ramdave Shakher, Lih-Ming Wong, Kim Taubman, Sze Ting Lee, Edward Hsiao, Paul Roach, Michelle Nottage, Ian Kirkwood, Dickon Hayne, Emma Link, Petra Marusic, et al.

Journal article  |  2020  |  The Lancet

BACKGROUND: Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised pro..

Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)

Andrew James Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, Laura Galleta, Amanda Seegum, Alan Herschtal, Emma Link, Margaret Mary McJannett, Elizabeth Chien Hern Liow, Peter S Grimison, Alison Yan Zhang, Nitya Patanjali, Siobhan Ng, Robert Goodwin, Colin Tang, Colin Chen, Elizabeth J Hovey, George Hruby, Alexander David Guminski, Ian D Davis

Conference Proceedings  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (F-18) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors

Mei Sim Lung, Rodney J Hicks, Nick Pavlakis, Emma Link, Michael Jefford, Benjamin Thomson, David K Wyld, Winston Liauw, Timothy Akhurst, Narmatha Kuru, Michael Michael

Journal article  |  2020  |  Asia-Pacific Journal of Clinical Oncology

AIMS: This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrin..

International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast

Ivo A Olivotto, Emma Link, Claire Phillips, Timothy J Whelan, Guy Bryant, Ian H Kunkler, A Helen Westenberg, Kash Purohit, Verity Ahern, Peter H Graham, Mohamed Akra, Orla McArdle, Joanna J Ludbrook, Jennifer A Harvey, John H Maduro, Carine Kirkove, Guenther Gruber, Joseph D Martin, Ian D Campbell, Geoff P Delaney, et al.

Journal article  |  2020  |  Radiotherapy and Oncology

PURPOSE: To assess the cosmetic impact of breast conserving surgery (BCS), whole breast irradiation (WBI) fractionation and tumour..

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai

Journal article  |  2019  |  Contemporary Clinical Trials Communications

Background: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid c..

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study

Amit Khot, Natalie Brajanovski, Donald P Cameron, Nadine Hein, Kylee H Maclachlan, Elaine Sanij, John Lim, John Soong, Emma Link, Piers Blombery, Ella R Thompson, Andrew Fellowes, Karen E Sheppard, Grant A McArthur, Richard B Pearson, Ross D Hannan, Gretchen Poortinga, Simon J Harrison

Journal article  |  2019  |  Cancer Discovery

RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) is tightly regulated downstream of oncogenic pathways, and it..

Utility of routine oral contrast study for detecting postesophagectomy anastomotic leak - a systematic review and meta-analysis

G Yonis, CS Cabalag, E Link, CP Duong

Journal article  |  2019  |  Diseases of the Esophagus

Oral contrast studies are used to detect anastomotic leak (AL) postesophagectomy. However, recent evidence suggests oral contrast ..

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

Michael Michael, Rachel Wong, Sanjeev Singh Gill, David Goldstein, Sam Ngan, Alexander Graham Heriot, Emma Link, Maria Farrell, Paul J Neeson, Robert George Ramsay, Kasmira Wilson, Catherine Mitchell, Jeanne Tie, Nick Pavlakis, John Raymond Zalcberg, Eva Segelov

Conference Proceedings  |  2019  |  Journal of Clinical Oncology